Drug Profile
Research programme: antibacterials - Vaxart
Alternative Names: Benzothiazole urea based inhibitors -Vaxart; CDI-538 series antibacterials - Prolysis; CDI-936 series antibacterials - Prolysis; GYR-767 series antibacterials - Prolysis; PC-190708; PC-190723Latest Information Update: 16 Feb 2018
Price :
$50
*
At a glance
- Originator Prolysis
- Developer Aviragen Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Small molecules
- Mechanism of Action Cell division inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Clostridium difficile infections; Pneumonia; Skin and soft tissue infections; Staphylococcal infections
Most Recent Events
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (IV)
- 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (PO)